Biosimilar Development News
-
Biocon Biologics Concludes Integration Of Acquired Biosimilars Business In ~120 Countries
12/18/2023
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced the successful completion of the transition of the acquired biosimilars business in ~120 countries across Advanced and Emerging Markets, a year ahead of schedule.
-
Adalimumab (Humira) Biosimilars Pipeline Review 2023
12/14/2023
The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.
-
First Subject Dosed For Phase 1 Clinical Trial Of Henlius’ Ipilimumab Biosimilar HLX13
12/13/2023
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first subject was dosed for a phase 1 clinical trial of the company's independently developed ipilimumab biosimilar HLX13 (recombinant anti-CTLA-4 fully human monoclonal antibody injection) in China.
-
Commencement Of Construction In Lendava: The Largest Investment In Lek's History In Line With Plans
12/12/2023
The first stage of the construction of Lek's new high-tech biopharmaceutical production center was launched today in Lendava with the assembly of a DNA double helix to commemorate the70th anniversary of its discovery, which laid the foundations for the development of biologics and biosimilars.
-
VEGZELMA® (bevacizumab-adcd) Receives Preferred Formulary Status With Ventegra® For Commercially Insured Patients
12/11/2023
elltrion USA today announced that Ventegra®, a major U.S. Medical Benefits Manager (MBM) who administers pharmacy benefits through its Pharmacy Services Administration (PSA) model, will place an FDA-approved biosimilar to Avastin® (bevacizumab), VEGZELMA® (bevacizumab-adcd), on its commercial formulary as a preferred brand.
-
FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), A Biosimilar Referencing Avastin®
12/7/2023
Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, today announced that the United States Food and Drug Administration (FDA) has approved Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®.
-
Health Canada Approves FYB201/Ranopto (Ranibizumab), A Biosimilar To Lucentis
12/7/2023
Formycon AG, Polpharma Biologics Group BV, Bioeq AG and Teva Canada Ltd. jointly announce that Health Canada has granted the “Notice of Compliance” (NOC) for Ranopto1 (Ranibizumab), a biosimilar to Lucentis2, for the treatment of several serious retinal diseases in Canada.
- Health Canada Approves FYB201/Ranopto (Ranibizumab), A Biosimilar To Lucentis 12/7/2023
-
Biosimulation Market To Reach USD 12.7 Billion By 2032 Report By DataHorizzon Research
12/6/2023
According to DataHorizzon Research, The Biosimulation Market size was valued at USD 2.8 Billion in 2022 and is anticipated to reach USD 12.7 Billion by 2032 with a CAGR of 16.6%.
-
Fresenius Kabi And Formycon Announce FDA Submission Acceptance For Review For Ustekinumab Biosimilar Candidate
11/30/2023
Fresenius Kabi and its license partner Formycon announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for FYB202, a Ustekinumab biosimilar candidate.